The Antiplatelet Effect of Six Non-Steroidal Anti-Inflammatory Drugs and Their Pharmacodynamic Interaction With Aspirin in Healthy Volunteers

American Journal of Cardiology

Volumn 101, Issue 7, 2008, Pages 1060-1063

  Gladding, Patrick A ^a   Webster, Mark W I ^a   Farrell, Helen B ^a   Zeng, Irene S L ^a   Park, Robert ^a   Ruijne, Nicola ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; CELECOXIB; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RHEUMACIN 25; SULINDAC; SURGAM SA; TIAPROFENIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATAXIA; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOUBLE BIND INTERACTION; DRUG ANTAGONISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TIME FACTORS;

EID: 41249103710     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.054     Document Type: Article

References (20)

1. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
2. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
3. Rao G.H., Johnson G.G., Reddy K.R., and White J.G. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 3 (1983) 383-388
4. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., Vyas S.N., and Fitzgerald G.A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
5. Cryer B., Berlin R.G., Cooper S.A., Hsu C., and Wason S. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 27 (2005) 185-191
6. Livio M., Del Maschio A., Cerletti C., and De Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 23 (1982) 787-796
7. Capone M.L., Sciulli M.G., Tacconelli S., Grana M., Ricciotti E., Renda G., Di Gregorio P., Merciaro G., and Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45 (2005) 1295-1301
8. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
9. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., and Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
10. ten Berg J.M., Gerritsen W.B., Haas F.J., Kelder H.C., Verheugt F.W., and Plokker H.W. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb Res 105 (2002) 385-390
11. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., and Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
12. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2002) 37-42
13. Grau A.J., Reiners S., Lichy C., Buggle F., and Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 34 (2003) 849-854
14. Ziegler S., Maca T., Alt E., Speiser W., Schneider B., and Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13 (2002) 493-497
15. Kurth T., Glynn R.J., Walker A.M., Chan K.A., Buring J.E., Hennekens C.H., and Gaziano J.M. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108 (2003) 1191-1195
16. Gislason G.H., Jacobsen S., Rasmussen J.N., Rasmussen S., Buch P., Friberg J., Schramm T.K., Abildstrom S.Z., Kober L., Madsen M., and Torp-Pedersen C. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113 (2006) 2906-2913
17. Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., Di Gregorio P., Merciaro G., Patrono C., and Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1471
18. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
19. Ouellet M., Riendeau D., and Percival M.D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A 98 (2001) 14583-14588
20. Wilner K.D., Rushing M., Walden C., Adler R., Eskra J., Noveck R., and Vargas R. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 42 (2002) 1027-1030